A closer look at depression and its relationship to HIV antiretroviral adherence

Annals of Behavioral Medicine

Volumn 42, Issue 3, 2011, Pages 352-360

  Wagner, Glenn J ^a   Goggin, Kathy ^b   Remien, Robert H ^c   Rosen, Marc I ^d   Simoni, Jane ^e   Bangsberg, David R ^f   Liu, Honghu ^g  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HARVARD UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral adherence; Cognitive depressive symptoms; Depression; HIV AIDS

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEPRESSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REGRESSION ANALYSIS; SOCIOECONOMICS; TIME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84857040879     PISSN: 08836612     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12160-011-9295-8     Document Type: Article

References (45)

1. Bing EG, BurnamMA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001; 58(8): 721-8. (Pubitemid 32717795)
2. Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: Results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11:75-82. (Pubitemid 34947050)
3. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725-730. (Pubitemid 32429839)
4. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Inter Med. 2000; 160(14): 2101-7. (Pubitemid 30482715)
5. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31: S136-9. (Pubitemid 35453574)
6. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of selfreported adherence in persons living with HIV disease. AIDS Patient Care and STDs. 1999; 13(3): 185-97. (Pubitemid 29155987)
7. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004; 45(5): 394-402. (Pubitemid 39166911)
8. Vranceanu AM, Safren SA, Lu M, CoadyWM, Skolnik PR, Rogers WH, Wilson IB. The relationship of post-traumatic stress disorder and depression to antiretroviralmedication adherence in persons with HIV. AIDS Patient Care and STDs. 2007; 22: 313-21.
9. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004; 16(4): 501-6. (Pubitemid 38651066)
10. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care and STDs. 2008; 22: 231-41.
11. Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care and STDs. 2002; 16 (5): 233-40. (Pubitemid 34478163)
12. Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999; 14: 446-8.
13. Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: Results from the Steps Study. AIDS Behav. 2011; 15(6):1161-1170
14. Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007; 44 (4): 411-6. (Pubitemid 46555375)
15. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000; 23(5): 396-404. (Pubitemid 30431596)
16. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999; 21 (2): 114-9. (Pubitemid 29250074)
17. Wood E, Montaner JS, Bangsberg DR, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003; 17(17): 2419-27. (Pubitemid 38393313)
18. Safren SA, O'Cleirigh CO, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009; 28: 1-10.
19. Wagner GJ. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clinical Trials. 2003; 4(4): 269-81.
20. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDs. 2002; 16(12): 599-608. (Pubitemid 36008059)
21. Weidle PJ, Ganea CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr. 1999; 22(5): 498-502. (Pubitemid 30027501)
22. Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care and STDs. 2004; 18(7): 385-93. (Pubitemid 38989017)
23. Wing RR, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. J Psychosom Res. 2002; 53(4): 877-81. (Pubitemid 35282617)
24. Antoni MH, Carrico AW, Duran RE, et al. Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med. 2006; 68(1): 143-51. (Pubitemid 43803229)
25. Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005; 38(4): 432-8. (Pubitemid 40381553)
26. Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001; 16(9): 625-33. (Pubitemid 32823894)
27. Walkup J, Wei W, Sambamoorthi U, Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q. 2008; 79(1): 43-53.
28. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008; 47(3): 384-90. (Pubitemid 351619427)
29. Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP. Assessing antiretroviral adherence via electronic drug monitoring and selfreport: An examination of key methodological issues. AIDS Behav. 2007; 11:161-73.
30. Wagner GJ, Kanouse DE, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to ART: A randomized controlled trial (CCTG 578). AIDS. 2006; 20:1295-1302. (Pubitemid 44030379)
31. Finocchario-Kessler S, Catley D, Berkley-Patton J, et al. Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: The role of patient autonomy and fatalistic religious beliefs. AIDS Patient Care STDs. 2011;25:103-111.
32. Beck AT, Steer RA, Brown GK (1996) BDI-II manual. The Psychological Corporation Harcourt Brace & Company, San Antonio
33. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988; 8: 77-100. (Pubitemid 18045797)
34. Radloff LS. The CES-D scale: A self report depression scale for research in the general population. Applied Psychological Measurement. 1977; 1: 385-401.
35. Derogatis LR. Brief Symptom Inventory 18: Administration, scoring, and procedures manual. Minneapolis, MN: NCS Pearson, Inc. 2001.
36. Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M. Early increase in vegetative symptoms predicts IFN-α-induced cognitivedepressive changes. Psychological Med. 2005; 35:433-441. (Pubitemid 40372481)
37. Sunnil SB, Gelfand LA, Schmid SP, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. J Affective Dis. 2008; 110:161-6.
38. Faustman WO, Faull KF, Whiteford HA, Borchert C, Csernansky JG. CSF 5-HIAA, serum cortisol, and age differentially predict vegetative and cognitive symptoms in depression. Biological Psychiatry. 1990; 27:311-8. (Pubitemid 20055787)
39. Spitznagel MB, Tremont G, Brown LB, Gunstad J. Cognitive reserve and the relationship between depressive symptoms and awareness of deficits in dementia. J Neuropsychiatry Clin Neurosci. 2006; 18:186-190.
40. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982; 38: 963-974.
41. Diggle PJ, Liang KY, Zeger SL. The analysis of longitudinal data. Oxford University Press, Oxford, 1994.
42. Treisman G, Lyketsos CG, Fishman M, Hanson AL, Rosenblatt A, McHugh PR. Psychiatric care for patients with HIV infection: The varying perspectives. Psychosomatics. 1993; 34(5): 432-9. (Pubitemid 23260962)
43. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of protease inhibitors in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001; 2:38-45. (Pubitemid 32181748)
44. Simoni JM, Safren SA, Manhart LE, et al. Challenges in addressing depression in HIV research: Assessment, cultural context, and methods. AIDS & Behavior. 2011; 15(2):376-388.
45. Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry. 2010; 67: 1-9.